Claims for Patent: 7,097,971

Summary for Patent: 7,097,971

Title:	HIV-1 peptide, antigen, immunogenic composition, diagnostic method and immunoassay kit
Abstract:	The present invention comprises novel and modified peptides capable of inducing a HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV Tat and Rev, regulatory proteins and Nef, auxiliary proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.
Inventor(s):	Sorensen; Birger (Skien, NO)
Assignee:	Bionor Immuno AS (Skien, NO)
Application Number:	10/129,333
Patent Claims:	1. A composition comprising an isolated HIV peptide comprising an amino acid sequence of Phe Val Ile His Arg Leu Glu Pro Trp Leu His Pro Gly Ser Gln His Nle Thr Ala Ser Thr Asn (SEQ ID NO: 14), wherein the terminal ends of the sequence may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, and two or more of the Cys residues may form part of an intrachain- or interchain-disulfide bond, a --S--(CH.sub.2).sub.p--S-- or a --(CH.sub.2).sub.p-bridge wherein p=1 8 optionally intervened by one or more heteroatoms such as O, N and S and/or the peptide is immobilized to a solid support. 2. An antigen comprising the peptide according to claim 1. 3. An immunogenic composition comprising the antigen according to claim 2 with a pharmaceutically acceptable diluent and optionally an adjuvant, carrier and/or vehicle and optionally additional immunostimulatory compound(s). 4. The immunogenic composition according to claim 3, wherein the peptide is dissolved in a sterile water solution and the optional immunostimulatory compound is a granulocyte macrophage colony stimulating factor. 5. The immunogenic composition according to claim 3, wherein the composition comprises an adjuvant selected from the group consisting of Monophosphoryl Lipid A (MPL.RTM.), Freund's complete adjuvant, Freund's incomplete adjuvant and aluminum hydroxide. 6. The immunogenic composition according to 3, wherein the antigen is formulated as a lipopeptide and/or a liposome formulation. 7. A method of detecting antibodies, induced by a HIV or HIV-specific peptide(s) or protein(s), in a sample of body fluid, comprising; contacting the sample with the peptide according to claim 1 under conditions such that antigen-antibody binding occurs; and detecting bound antibodies. 8. An immunoassay kit for the detection of antibodies, induced by a HIV or HIV-specific peptides or proteins, in a sample of body fluid, comprising the peptide according to claim 1. 9. The composition according to claim 1, further comprising an isolated HIV peptide selected from the group consisting of: (1) Cys Ser Trp Val Asn Pro Arg Leu Glu Pro Trp Nle His Pro Gly Ser Gln His Nle Thr Ala Cys Thr Asn (SEQ ID NO: 2); and (2) Phe Val Ile Pro Arg Leu Glu Pro Trp Nle His Pro Gly Ser Gln Pro Nle Thr Ala Cys Thr Asn (SEQ ID NO: 3), wherein the terminal ends of the sequence may be free carboxyl- or amino groups, amides, acyls, acetyls or salts thereof, and two or more of the Cys residues may form part of an intrachain- or interchain-disulfide bond, a --S--(CH.sub.2).sub.p--S-- or a --(CH.sub.2).sub.p-bridge wherein p=1 8 optionally intervened by one or more heteroatoms such as O, N and S and/or the peptide is immobilized to a solid support.

Details for Patent 7,097,971

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2020-09-04